Non-small-cell lung cancer: how to manage EGFR-mutated disease

Area of Science:

• Oncology
• Molecular Biology
• Genetics

Background:

• Epidermal Growth Factor Receptor (EGFR) mutations are key drivers in non-small-cell lung cancer (NSCLC).
• Osimertinib, a third-generation EGFR tyrosine kinase inhibitor (TKI), has significantly impacted first-line and adjuvant treatment for common EGFR mutations (Ex19del, L858R).
• Next-generation sequencing (NGS) reveals uncommon and compound EGFR mutations, contributing to TKI resistance.

Purpose of the Study:

• To summarize recent advancements in targeting EGFR-mutated advanced NSCLC.
• To discuss the biological mechanisms of primary and secondary resistance to EGFR-TKIs.
• To propose a treatment algorithm based on current data for EGFR-mutant NSCLC.

Main Methods:

• Literature review of recent studies on EGFR-mutated NSCLC treatments.
• Analysis of next-generation sequencing data for mutation profiling.
• Discussion of emerging therapeutic strategies, including TKI combinations and antibody-drug conjugates.

Main Results:

• Osimertinib has become a standard of care for specific EGFR mutations in NSCLC.
• NGS has expanded the understanding of EGFR mutation landscape and resistance mechanisms.
• Novel therapeutic combinations and antibody-drug conjugates are under investigation.

Conclusions:

• Continued research into resistance mechanisms is crucial for developing next-generation therapies.
• Personalized treatment strategies incorporating advanced molecular profiling are essential.
• A data-driven treatment algorithm can guide clinical decision-making for EGFR-mutant NSCLC.